Document Detail


ACE inhibitors and protection against kidney disease progression in patients with type 2 diabetes: what's the evidence.
MedLine Citation:
PMID:  12461306     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Although angiotensin-converting enzyme inhibitors are frequently used as antihypertensive agents to lower blood pressure and slow progression of nephropathy in patients with type 2 diabetes, evidence of their efficacy has been drawn primarily from small trials with surrogate end points. No adequately powered, long-term trials have tested their effects to reduce the incidence of hard end points, such as progression to end-stage renal disease or even doubling of serum creatinine in the population of patients with nephropathy from type 2 diabetes. While the results of angiotensin-converting enzyme inhibitor trials from nondiabetic causes and even type 1 diabetes may be extrapolated to the patient with nephropathy associated with type 2 diabetes, the hard evidence is not available. This review critically evaluates the limited evidence in support of angiotensin-converting enzyme inhibitors as renal-protective agents in people with type 2 diabetes.
Authors:
George L Bakris; Matthew Weir
Related Documents :
15822056 - Predicting the development of diabetic nephropathy and its progression.
16899516 - Renal bone morphogenetic protein-7 protects against diabetic nephropathy.
3047956 - Renal replacement treatment for diabetic nephropathy in northern ireland 1979-1987.
6581776 - Alteration in prostacyclin and prostaglandin e2 production. correlation with changes in...
2507376 - Whole-plasma and high-density lipoprotein subfraction surface lipid composition in iddm...
21376466 - Hypoxia-induced sensitization of transient receptor potential vanilloid 1 involves acti...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Journal of clinical hypertension (Greenwich, Conn.)     Volume:  4     ISSN:  1524-6175     ISO Abbreviation:  J Clin Hypertens (Greenwich)     Publication Date:    2002 Nov-Dec
Date Detail:
Created Date:  2002-12-03     Completed Date:  2003-04-03     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  100888554     Medline TA:  J Clin Hypertens (Greenwich)     Country:  United States    
Other Details:
Languages:  eng     Pagination:  420-3     Citation Subset:  IM    
Copyright Information:
Copyright 2002 Le Jacq Communications, Inc.
Affiliation:
Department of Preventive Medicine, Rush-Presbyterian-St. Lukes Medical Center, Chicago, IL 60612, USA. gbakris@rush.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Angiotensin-Converting Enzyme Inhibitors / therapeutic use*
Clinical Trials as Topic
Diabetes Mellitus, Type 2 / drug therapy*,  enzymology,  physiopathology
Diabetic Nephropathies / drug therapy*,  enzymology
Disease Progression
Humans
Kidney Failure, Chronic / drug therapy*,  enzymology
Chemical
Reg. No./Substance:
0/Angiotensin-Converting Enzyme Inhibitors

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Effectiveness of the electronic medical record in improving the management of hypertension.
Next Document:  Sexual dysfunction in patients with hypertension: implications for therapy.